BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28095380)

  • 1. Polycythemia Vera Management and Challenges in the Community Health Setting.
    Gerds AT; Dao KH
    Oncology; 2017; 92(4):179-189. PubMed ID: 28095380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.
    Kuykendall AT
    Ann Hematol; 2023 May; 102(5):985-993. PubMed ID: 36944847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.
    Altomare I; Parasuraman S; Paranagama D; Kish J; Lord K; Yu J; Colucci P
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e915-e921. PubMed ID: 34353779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
    Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
    Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycythemia vera: current pharmacotherapy and future directions.
    Hensley B; Geyer H; Mesa R
    Expert Opin Pharmacother; 2013 Apr; 14(5):609-17. PubMed ID: 23480062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.
    Kremyanskaya M; Mascarenhas J; Hoffman R
    Expert Opin Pharmacother; 2015 Jun; 16(8):1185-94. PubMed ID: 25873215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
    Nazha A; Gerds AT
    Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
    Reiter A; Harrison C
    Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
    Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
    Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hydroxyurea resistant or intolerant polycythemia vera.
    Raman I; Pasricha SR; Prince HM; Yannakou CK
    Leuk Lymphoma; 2021 Oct; 62(10):2310-2319. PubMed ID: 33949918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
    Maffioli M; Mora B; Passamonti F
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.
    Crodel CC; Jentsch-Ullrich K; Reiser M; Jacobasch L; Sauer A; Tesch H; Ulshöfer T; Wunschel R; Palandri F; Heidel FH
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2693-2705. PubMed ID: 34807311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
    Theocharides A; Gisslinger H; De Stefano V; Accurso V; Iurlo A; Devos T; Egyed M; Lippert E; Delgado RG; Cantoni N; Dahm AEA; Sotiropoulos D; Houtsma E; Smyth A; Iqbal A; Di Matteo P; Zuurman M; Te Boekhorst PAW
    Eur J Haematol; 2024 Mar; 112(3):379-391. PubMed ID: 37899734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
    Nazha A; Khoury JD; Verstovsek S; Daver N
    Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
    Kiladjian JJ; Guglielmelli P; Griesshammer M; Saydam G; Masszi T; Durrant S; Passamonti F; Jones M; Zhen H; Li J; Gadbaw B; Perez Ronco J; Khan M; Verstovsek S
    Ann Hematol; 2018 Apr; 97(4):617-627. PubMed ID: 29396713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
    Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
    Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
    Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
    Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.
    Griesshammer M; Saydam G; Palandri F; Benevolo G; Egyed M; Callum J; Devos T; Sivgin S; Guglielmelli P; Bensasson C; Khan M; Ronco JP; Passamonti F
    Ann Hematol; 2018 Sep; 97(9):1591-1600. PubMed ID: 29804268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
    Vannucchi AM; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Mesa R; He S; Jones MM; Garrett W; Li J; Pirron U; Habr D; Verstovsek S
    N Engl J Med; 2015 Jan; 372(5):426-35. PubMed ID: 25629741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.